Raffles Associates LP Lineage Cell Therapeutics, Inc. Transaction History
Raffles Associates LP
- $78.5 Million
- Q2 2024
A detailed history of Raffles Associates LP transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Raffles Associates LP holds 4,357,781 shares of LCTX stock, worth $3.62 Million. This represents 5.55% of its overall portfolio holdings.
Number of Shares
4,357,781
Previous 3,209,981
35.76%
Holding current value
$3.62 Million
Previous $4.75 Million
8.27%
% of portfolio
5.55%
Previous 5.99%
Shares
12 transactions
Others Institutions Holding LCTX
# of Institutions
123Shares Held
94.4MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$34.6 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$7.93 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.03 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$4.15 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$3.9 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $141M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...